您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Tocilizumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tocilizumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
Tocilizumab (Anti-Human IL6R, Humanized Antibody) 是一种抗人白细胞介素 6 受体 (IL-6R) 中和抗体,可防止 IL-6 与 IL-6R 结合,从而抑制经典和反式信号传导。

Cell lines

U266B1 cells

Preparation Method

Cell Proliferation Assays U266B1 cells were suspended with SOMAmer (1, 10, or 100 μg/ml) or tocilizumab (1, 10, or 100 μg/ml) in RPMI 1640 medium containing 10% FBS at 104 cells per well and cultured for 30 min at 37 ℃ in a 5% CO2 incubator.

Reaction Conditions

1, 10, or 100 μg/ml,30 min at 37 ℃

Applications

SL1026 achieved complete inhibition of IL-6 at 1 μg/ml (83 nm), whereas tocilizumab achieved 60% inhibition at a roughly equivalent molar concentration (67 nm) .

Animal models

Patients with rheumatoid arthritis

Preparation Method

Patients (n=1262) were randomised 1:1 to receive Tocilizumab-SC 162 mg weekly (qw)+placebo-IV every four weeks (q4w) or Tocilizumab-IV 8 mg/kg q4w+placebo-SC qw in combination with DMARD(s). Maintenance of clinical responses and safety through week 97 were assessed.

Dosage form

8 mg/kg; SC,IV

Applications

Tocilizumab-SC had a comparable safety profile to Tocilizumab-IV through week 97, except that injection site reactions (ISRs) were more common with Tocilizumab-SC. Safety profiles in patients who switched were similar to those in patients who received continuous Tocilizumab-SC or Tocilizumab-IV treatment.

产品描述

Tocilizumab, as a humanised monoclonal antibody, can target both membrane-bound and soluble forms of the IL-6 receptor.[1]Tocilizumab has been approved for treatment in patients with rheumatologic disorders and chimeric antigen receptor T cell-induced cytokine release syndrome.[3]

In vitro efficacy test it shown that treatment with tocilizumab (1 or 10 μm) or SOMAmer (0.83 or 8.3 μm), SOMAmer suppressed the proliferation of U87MG and HepG2 cells to a greater extent than tocilizumab at similar molar concentrations.[7]

In vivo efficacy test it indicated that treatment with 8 mg/kg tocilizumab using two consecutive intravenous infusions 12 h apart in 100 patients with COVID-19 and ARDS requiring ventilatory support in Brescia (Italy) has 20% mortality according to an optional third infusion based on clinical response.[1]In vivo, tocilizumab 8 mg/kg × 1 in mechanically ventilated patients, the results shown that receipt of tocilizumab was independently associated with improved survival.[2]In vivo study for the treatment of rheumatoid arthritis, treatment with 4 mg/kg tocilizumab, the results exhibited that the average IL-6 level reached the peak at the second week after administration, and then decreased gradually.[4]In a 61-year-old man with COVID-19, treatment with 324 mg Tocilizumab via subcutaneous with hydroxychloroquine can successfully manage the infection.[6]In addition, the recommended dose of Tocilizumab is 4–8 mg/kg administered as a single 60- minute intravenous infusion every 4 weeks for treatment in moderate to severe active arthritis in adults, Giant cell arthritis, Polyarticular juvenile idiopathic arthritis and cytokine release syndrome in patients 2 years of age older with active disease.[5]

References:
[1] Lan SH, et al. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep;56(3):106103.
[2]Somers EC, et al. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Clin Infect Dis. 2021 Jul 15;73(2):e445-e454.
[3]Wei Q, et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty. 2021 May 18;10(1):71.
[4]Smolen J.S, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997.
[5]Sebba A, et al. Tocilizumab: the first interleukin -6 receptor inhibitor. Am J Health Syst Pharm. 2008;65(15):1413–1418.
[6]Fontana F, et al. Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine. Am. J. Transplant. American J. Transplant. 2020;20(7).
[7]Gupta S, et al. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. J Biol Chem. 2014 Mar 21;289(12):8706-19.